CN113318126A - Technology for treating HPV infected patient - Google Patents
Technology for treating HPV infected patient Download PDFInfo
- Publication number
- CN113318126A CN113318126A CN202110662897.4A CN202110662897A CN113318126A CN 113318126 A CN113318126 A CN 113318126A CN 202110662897 A CN202110662897 A CN 202110662897A CN 113318126 A CN113318126 A CN 113318126A
- Authority
- CN
- China
- Prior art keywords
- hpv
- cells
- patients
- positive
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000005516 engineering process Methods 0.000 title abstract description 13
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 41
- 238000009169 immunotherapy Methods 0.000 claims abstract description 5
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims abstract 8
- 241000701806 Human papillomavirus Species 0.000 claims description 42
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 238000004113 cell culture Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 210000001215 vagina Anatomy 0.000 claims description 6
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 5
- 238000013329 compounding Methods 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 230000002085 persistent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 8
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 4
- 230000007123 defense Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000012930 cell culture fluid Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Abstract
The invention relates to the technical field of disease treatment, in particular to a technology for treating HPV infected patients, which improves the cure rate of HPV positive patients; control and treatment of HPV positive patients using NK cell adoptive immunotherapy.
Description
Technical Field
The invention relates to the technical field of disease treatment, in particular to a technology for treating HPV infected patients.
Background
Cervical cancer is a common malignant tumor in women, and epidemiological and molecular biological data show that Human Papilloma Virus (HPV) infection is closely related to cervical cancer. Screening for cervical cancer can reduce the risk of developing cervical cancer, but cannot prevent HPV infection. At present, no definite treatment method for HPV infection exists, and how to quickly convert HPV positive patients to negative is an important means for preventing cervical cancer by blocking HPV infection.
In most female populations, despite the fact that they have been infected with HPV, there are sufficient immune defense mechanisms to trigger cellular, humoral, etc. immunity to clear the virus. It has been proved that DC cells, NK cells and the like participate in innate immune response at the early stage of HPV virus infection of a host, and a system consisting of these cells with innate immune response is the first line of defense against infection. In the early stage of HPV virus infection, the appearance of NK cells effectively blocks the lysis process of infected cells, and plays a positive defense role. After the host is infected by HPV, the ability of NK cell surface killing and activating receptor is affected and gradually weakened, and the process weakens the defense effect of NK cells, and further promotes the spread and persistence of HPV infection in the host.
Disclosure of Invention
In order to solve the technical problems, the invention provides a technology for treating HPV infected patients, which can improve the cure rate of HPV positive patients.
The technology for treating the HPV infected patient applies the NK cell adoptive immunotherapy to control and treat the HPV positive patient.
The invention relates to a technology for treating HPV infected patients, which comprises the following steps:
extracting NK cells from a human papilloma virus positive patient;
preparing liquid gel by compounding with NK cell culture;
③ the HPV positive patients use autologous NK cells to be injected into the body;
fourthly, injecting the liquid gel into the vagina locally;
carrying out regular follow-up after the treatment course is finished;
sixthly, registering a pathology report.
The invention relates to a technology for treating HPV infected patients, and the HPV positive patients adopt autologous NK cell intravenous drip.
The invention relates to a technology for treating HPV infected patients, and NK cells are extracted from high-risk HPV continuous positive patients.
Compared with the prior art, the invention has the beneficial effects that: the cure rate of HPV positive patients is improved.
Detailed Description
The following examples are given to further illustrate the embodiments of the present invention. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
The technology for treating the HPV infected patient applies the NK cell adoptive immunotherapy to control and treat the HPV positive patient; the cure rate of HPV positive patients is improved.
The invention relates to a technology for treating HPV infected patients, which comprises the following steps:
extracting NK cells from a human papilloma virus positive patient;
preparing liquid gel by compounding with NK cell culture;
③ the HPV positive patients use autologous NK cells to be injected into the body;
fourthly, injecting the liquid gel into the vagina locally;
carrying out regular follow-up after the treatment course is finished;
sixthly, registering a pathology report.
The invention relates to a technology for treating HPV infected patients, and the HPV positive patients adopt autologous NK cell intravenous drip.
The invention relates to a technology for treating HPV infected patients, and NK cells are extracted from high-risk HPV continuous positive patients.
Case one
HPV positive patients were treated with autologous NK cell intravenous drip (2 consecutive times per treatment period, total cell count 1-1.6 x 16)101 time/day) is matched with local intravaginal perfusion (7 times continuously and 1 time/day in one treatment course) of NK cell culture solution gel for treatment, the HPV turning negative condition is observed after follow-up at 1, 3 and 6 months after the treatment course is finished, and the comprehensive effective rate is 86.5 percent.
Case two
HPV positive patients were treated with autologous NK cell intravenous drip (2 consecutive times per treatment period, total cell count 1-1.6 x 16)101 time/day) for self NK injection in multiple points in vagina and cervixCells (2 times per treatment course, total cell number 1-2 x 16)91 time/day), 5 days of injecting NK cell culture solution gel into vagina, 1, 3 and 6 months of follow-up after the treatment course is finished, observing the HPV negative turning condition, and ensuring that the comprehensive effective rate is 74.1 percent.
Third case
HPV positive patients were treated with autologous NK cell intravenous drip (2 consecutive times per treatment period, total cell count 1-1.6 x 16)101 time/day) is matched with local intravaginal perfusion (3 times and 1 time/day in one treatment course) of NK cell culture solution gel for treatment, the HPV turning negative condition is observed after 1, 3 and 6 months of follow-up after the treatment course is finished, and the comprehensive effective rate is 77.2 percent.
Four cases
Patients with HPV positive undergo vaginal intracervical multi-point injection of autologous NK cells (2 times per treatment course, total number of cells 1-2 x 16)91 time/day), 5 days of injecting NK cell culture solution gel into vagina, 1, 3 and 6 months of follow-up after the treatment course is finished, observing the HPV negative turning condition, and the comprehensive effective rate is 43.1%.
Typical case introduction one
Name: lady bag
Sex: woman
Age: 30
The return time is as follows: 2020.09.11-09.14
The treatment scheme comprises the following steps: NK cells 580U by 2 days, intravenous infusion of NK cell culture fluid gel by 4 days
Typical case introduction two
Name: plum lady
Sex: woman
Age: 51
The return time is as follows: 2020.09.10-09.15
The treatment scheme comprises the following steps: NK cells 520U 2 days, intravenous infusion of NK cell culture fluid gel 7 days
Introduction of typical cases
Name: lady horse
Sex: woman
Age: 40
The return time is as follows: 2020.08.30-09.05; 2020.12.08-12.14
The treatment scheme comprises the following steps: NK cells 800U x 2 days, intravenous infusion NK cell culture gel x 7 days; NK cells 800U by 2 days, intravenous infusion of NK cell culture solution gel by 7 days
The result shows that the application of the NK cell adoptive immunotherapy has good control and treatment effects on HPV positive patients and cervical carcinoma in situ patients. Similarly, the artificial increase of the number of cervical cells and NK cells in the peripheral environment can be used to prevent HPV colonization infection in cervical tissue by its immune killing effect.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and variations can be made without departing from the technical principle of the present invention, and these modifications and variations should also be regarded as the protection scope of the present invention.
Claims (4)
1. A technique for treating HPV infected patients, characterized by the use of NK cell adoptive immunotherapy for HPV positive patients control and treatment.
2. The technique of claim 1, wherein the treatment comprises:
extracting NK cells from a human papilloma virus positive patient;
preparing liquid gel by compounding with NK cell culture;
③ the HPV positive patients use autologous NK cells to be injected into the body;
fourthly, injecting the liquid gel into the vagina locally;
carrying out regular follow-up after the treatment course is finished;
sixthly, registering a pathology report.
3. The technique of treating a patient with HPV infection according to claim 1, wherein the HPV positive patient is treated by intravenous drip of autologous NK cells.
4. The technique of claim 1, wherein the NK cells are extracted from patients with high risk HPV persistent positive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110662897.4A CN113318126A (en) | 2021-06-15 | 2021-06-15 | Technology for treating HPV infected patient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110662897.4A CN113318126A (en) | 2021-06-15 | 2021-06-15 | Technology for treating HPV infected patient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113318126A true CN113318126A (en) | 2021-08-31 |
Family
ID=77420980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110662897.4A Pending CN113318126A (en) | 2021-06-15 | 2021-06-15 | Technology for treating HPV infected patient |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113318126A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070709A1 (en) * | 2015-10-23 | 2017-04-27 | The Regents Of The University Of Colorado A Body Corporate | Prognosis and treatment of squamous cell carcinomas |
| CN108815186A (en) * | 2018-06-14 | 2018-11-16 | 上海鸣大生物科技有限公司 | A kind of drug and preparation method and application treated HPV persistent infection and cause disease |
| CN112587632A (en) * | 2020-12-28 | 2021-04-02 | 海南启研干细胞抗衰老医院有限公司 | Biological preparation for preventing and treating HPV (human papillomavirus) infection and preparation method thereof |
| CN114075546A (en) * | 2020-08-20 | 2022-02-22 | 海南启研干细胞抗衰老医院有限公司 | NK cell amplification composition and in-vitro amplification culture method |
-
2021
- 2021-06-15 CN CN202110662897.4A patent/CN113318126A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070709A1 (en) * | 2015-10-23 | 2017-04-27 | The Regents Of The University Of Colorado A Body Corporate | Prognosis and treatment of squamous cell carcinomas |
| CN108463228A (en) * | 2015-10-23 | 2018-08-28 | 科罗拉多大学董事会法人团体 | The prognosis and treatment of squamous cell carcinoma |
| CN108815186A (en) * | 2018-06-14 | 2018-11-16 | 上海鸣大生物科技有限公司 | A kind of drug and preparation method and application treated HPV persistent infection and cause disease |
| CN114075546A (en) * | 2020-08-20 | 2022-02-22 | 海南启研干细胞抗衰老医院有限公司 | NK cell amplification composition and in-vitro amplification culture method |
| CN112587632A (en) * | 2020-12-28 | 2021-04-02 | 海南启研干细胞抗衰老医院有限公司 | Biological preparation for preventing and treating HPV (human papillomavirus) infection and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| XUNYAO WU等: "Reduced NK Cell Cytotoxicity by Papillomatosis-Derived TGF-β Contributing to Low-Risk HPV Persistence in JORRP Patients", 《FRONT IMMUNOL》 * |
| 李菡旖等: "自然杀伤细胞(NK细胞)治疗HPV阳性以及宫颈上皮瘤样的临床研究", 《世界最新医学信息文摘》 * |
| 马晓慧: "尖锐湿疣患者HPV感染类型和细胞免疫功能的分析", 《中国继续医学教育》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111840525B (en) | Composition for treating thromboangiitis and preparation method thereof | |
| CN110051773A (en) | A kind of gel and its preparation method that containing Camellia nitidissima there is antibacterial to repair cavity inflammation | |
| CN113318126A (en) | Technology for treating HPV infected patient | |
| CN102212505B (en) | Immune killer cell, preparation method thereof, medicinal composition containing immune killer cell and set | |
| CN110292558A (en) | A kind of cold treatment gel of cold compress and preparation method thereof | |
| CN1255135C (en) | Chinese traditional medicine perfusate for preventing and treating female livestock barrenness | |
| CN111281884A (en) | Method for reducing insulin dosage of diabetic patient by using stem cell therapy | |
| CN1291725C (en) | Nocardioactinomycetes cell wall skeleton preparation | |
| CN107722115A (en) | A kind of new restructuring bee venom peptide and its preparation method and application | |
| CN106692175A (en) | Application of miR-665-3p inhibitor to preparation of medicine for preventing and treating ischemia-reperfusion injuries | |
| CN110507736B (en) | A Chinese medicinal perfusate for treating endometritis of female animal, and its preparation method | |
| CN113244268A (en) | Bacteriostatic gel containing sulfated polysaccharide-nano silver complex and application thereof | |
| Sankar et al. | Therapeutic Management of intranasal transmissible venereal tumor in a Dog | |
| CN111358833A (en) | Prunella vulgaris extract and application thereof in preparation of medicines for treating thyroid diseases | |
| AU2021104085A4 (en) | Hpv-resistant lactic acid bacteria gynecological preparation and application thereof | |
| CN109692328A (en) | A kind of proteolytic enzyme preparation applied to treatment of cancer | |
| CN117582402B (en) | Gel containing leukocyte extract and preparation method and application thereof | |
| CN106267167A (en) | A kind of lactalbumin oleic acid complex and carrageenan composition of medicine and its preparation method and application | |
| CN106491645A (en) | One kind is used for treating physical property dermatosiss and the dermopathic external used medicine of animality and its preparation method and application | |
| CN110141609A (en) | It is a kind of for treating the ointment and preparation method thereof that children canthus is split | |
| CN106975073A (en) | Prevent and treat biomaterial preparation of mastitis for milk cows and preparation method thereof | |
| CN107184607A (en) | Application of people's synovioblast in treating rheumatoid arthritis | |
| SU1740004A1 (en) | Method for treating chronic prostatitis | |
| CN1218739C (en) | Application of Chinese lizardtail herb and its extractive in preventing and treating prostatosis | |
| CN1289102C (en) | Chinese-western medicine compound suppository for treating prostatic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210831 |